IPC분류정보
국가/구분 |
United States(US) Patent
등록
|
국제특허분류(IPC7판) |
|
출원번호 |
US-0488176
(2009-06-19)
|
등록번호 |
US-8425898
(2013-04-23)
|
발명자
/ 주소 |
- Sampson, John H.
- Mitchell, Duane A.
|
출원인 / 주소 |
|
대리인 / 주소 |
Womble Carlyle Sandridge & Rice, LLP
|
인용정보 |
피인용 횟수 :
1 인용 특허 :
23 |
초록
The present invention relates to compositions, methods, and kits for eliciting an immune response to at least one CMV antigen expressed by a cancer cell, in particular for treating and preventing cancer. CMV determination methods, compositions, and kits also are provided.
대표청구항
▼
1. A method for eliciting in a subject an immune response to a cancer cell that expresses a CMV antigen, the method comprising: selecting a subject in need of treatment related to the presence of the cancer cell; detecting the expression of the CMV antigen by the cancer cell in the subject, andadmin
1. A method for eliciting in a subject an immune response to a cancer cell that expresses a CMV antigen, the method comprising: selecting a subject in need of treatment related to the presence of the cancer cell; detecting the expression of the CMV antigen by the cancer cell in the subject, andadministering to the subject a pharmaceutically acceptable composition comprising at least one CMV antigen, wherein the pharmaceutically acceptable composition, when administered to the subject, elicits an immune response to the cancer cell. 2. The method of claim 1, wherein the at least one CMV antigen correspond to a polypeptide, or immunogenic fragment thereof, selected from the group consisting of: capsid polypeptides, tegument polypeptides, and envelop polypeptides. 3. The method of claim 1, wherein the at least one CMV antigen correspond to a polypeptide, or an immunogenic fragment thereof, selected from the group consisting of: phosphoprotein unique lon g83 (ppUL83; a/k/a pp65), glycoprotein UL55 (gpUL55; a/k/a gB), UL123 immediate early I (IE1) protein, UL122 IE2 protein, UL111A (a/k/a mtrII), US28, ppUL32, ppUL65, ppUL80a, ppUL82, ppUL98a, ppUL99, pgUL4, (a/k/a gp48), gpUL16, gpUL18, (a/k/a MHC), gpUL75 (a/k/a gH), gpUL100, gpUL110 (a/k/a gM), gpUL115 (a/k/a gL), pUL46, pUL48, pUL56, pUL86 (a/k/a MCP), glycoprotein unique short 10 (gpUS10), gpUS11, glycoprotein complex II (gcII), gp65, and pg93. 4. The method of claim 1, wherein the pharmaceutically acceptable composition further comprises at least one adjuvant, or a nucleic acid encoding the adjuvant. 5. The method of claim 4, wherein the adjuvant is a cytokine selected from the group consisting of: GM-CSF, G-CSF, IL-2, IL-4, IL-7, IL-12, IL-5, IL-21, TNF-α, and M-CSF. 6. The method of claim 1, wherein the at least one CMV antigen comprises an amino acid sequence corresponding to SEQ ID NO:109. 7. The method of claim 1, wherein the composition further comprises a glycoprotein UL55 (gpUL55; a/k/a gB) or an immunogenic fragment thereof. 8. The method of claim 1, wherein the composition further comprises a UL123 immediate early 1 (IE1) protein or an immunogenic fragment thereof.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.